BLA 761194 · Genzyme Corp
Nexviazyme
Avalglucosidase Alfa-Ngpt · Injection · Hydrolytic Lysosomal Glycogen-specific Enzyme
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Aug 6, 2021: To treat late-onset Pompe disease
Last checked: Nov 20, 2026Latest source record: Sep 15, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Aug 6, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
8
2 Phase 3, 3 recruiting
FAERS reports
998
210 serious, 8 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS See full prescribing information for complete boxed warning. Hypersensitivity Reactions Including Anaphylaxis Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, discontinue NEXVIAZYME immediately and initiate appropriate medical treatment. ( 5.1 ) Infusion-Associated Reactions (IARs) If severe IARs occur, consider immediate discontinuation and initiation of appropriate medical treatment. ( 5.2 ) Risk of Acute Cardiorespiratory Failure in Susceptible Patients Patients susceptible...
What it is approved for
From the label in effect Jun 5, 2025.
NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). NEXVIAZYME is a hydrolytic lysosomal glycogen-specific enzyme indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). ( 1 )
Mechanism: Pompe disease (also known as glycogen storage disease type II, acid maltase deficiency, and glycogenosis type II) is an inherited disorder of glycogen metabolism caused by a deficiency of the lysosomal enzyme acid α-glucosidase (GAA) that degrades glycogen to glucose in the lysosome. GAA deficiency results in intralysosomal accumulation of glycogen in various tissues. Avalglucosidase alfa-ngpt provides an exogenous source of GAA. The M6P on avalglucosidase alfa-ngpt mediates binding to M6P receptors on the cell surface with high affinity. After binding, it is internalized and transported into...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 15, 2023 Supplement 5 · Efficacy OrphanLetterLabel
- Aug 6, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- NEXVIAZYME · AVALGLUCOSIDASE ALFA-NGPT 100MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Avalglucosidase Alfa" as an intervention, any sponsor and status, largest first.
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02782741 · 101 participants · Start Nov 2, 2016 · Primary completion Mar 19, 2020
Drug: Avalglucosidase alfa (GZ402666); Alglucosidase alfa (GZ419829) · For: Glycogen Storage Disease Type II;Pompe's Disease
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 69 sites in all
- Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.Completed
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01898364 · 24 participants · Start Aug 19, 2013 · Primary completion Feb 25, 2015
Drug: GZ402666 · For: Pompe Disease; Glycogen Storage Disease Type II (GSD II); Acid Maltase Deficiency
Sites: Phoenix, Arizona; Jacksonville, Florida; Kansas City, Kansas · 17 sites in all
- A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase AlfaActive, not recruiting
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03019406 · 22 participants · Start Oct 12, 2017 · Primary completion Sep 30, 2019
Drug: Avalglucosidase alfa (GZ402666); Alglucosidase alfa (GZ419829) · For: Glycogen Storage Disease Type II-Pompe's Disease
Sites: Valhalla, New York; Durham, North Carolina; Seattle, Washington · 12 sites in all
- Avalglucosidase Alfa Extension StudyCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02032524 · 19 participants · Start Feb 27, 2014 · Primary completion Dec 12, 2022
Drug: Avalglucosidase Alfa · For: Glycogen Storage Disease Type II Pompe Disease
Sites: Phoenix, Arizona; Jacksonville, Florida; Kansas City, Kansas · 17 sites in all
- Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase AlfaPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT04910776 · 17 participants · Start Sep 1, 2021 · Primary completion Mar 2, 2026
Drug: avalglucosidase alfa · For: Glycogen Storage Disease Type II
Sites: Stanford, California; Minneapolis, Minnesota; Hawthorne, New York · 16 sites in all
- Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)Active, not recruiting
Genzyme, a Sanofi CompanySanofi (SNY)
NCT05164055 · 17 participants · Start Jul 11, 2022 · Primary completion Jun 30, 2027
Drug: Avalglucosidase alfa (GZ402666) · For: Glycogen Storage Disease Type II
Sites: Bordeaux, France; Brest, France; Clermont-Ferrand, France · 11 sites in all
- China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDRecruiting
Genzyme, a Sanofi CompanySanofi (SNY)
NCT06666413 · 13 participants (planned) · Start May 7, 2025 · Primary completion May 2, 2028
Drug: Avalglucosidase alfa · For: Glycogen Storage Disease Type II; Pompe's Disease
Sites: Shanghai, China
- Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 YearsActive, not recruiting
Iris PlugAcademic, hospital or other
NCT07652814 · 6 participants (planned) · Start Oct 13, 2022 · Primary completion Mar 9, 2028
Drug: Avalglucosidase Alfa · For: Glycogen Storage Disease Type II Late Onset; Pompe Disease (Late-onset); Pompe Disease Late-Onset and 2 more
Sites: Rotterdam, Netherlands
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug specific antibody present150
- off label use100
- weight increased64
- inappropriate schedule of product administration52
- weight decreased46
- pyrexia39
- fatigue36
- dyspnoea35
- condition aggravated32
- illness32
- fall28
- headache28
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 22 |
| 2022 | 148 |
| 2023 | 195 |
| 2024 | 212 |
| 2025 | 221 |
| 2026 | 200 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nexviazyme (Avalglucosidase Alfa-Ngpt)
2024 spending
$34.7M
Beneficiaries
53
618 claims
Per beneficiary
$655,496
$1,817.49 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $948,652 |
| 2022 | $15,142,060 |
| 2023 | $21,526,673 |
| 2024 | $34,741,263 |
Part B: Nexviazyme (Avalglucosidase Alfa-Ngpt) · HCPCS J0219
2024 spending
$73.8M
Beneficiaries
122
2,092 claims
Per beneficiary
$604,977
2024 ASP limit $76.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $33,477,990 |
| 2023 | $67,248,349 |
| 2024 | $73,807,184 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J, Kishnani PS, Kushlaf H, et al. · Lancet Neurol 2021 · Multicenter Study, Randomized Controlled Trial
- Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS, Diaz-Manera J, Toscano A, et al. · JAMA Neurol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.
Kronn D, Davison J, Broomfield A, et al. · J Pediatr 2025 · Clinical Trial, Phase II, Multicenter Study
- Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial.
Kishnani PS, Díaz-Manera J, Illarioshkin S, et al. · J Neurol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.
Berger KI, Ivanescu C, Msihid J, et al. · J Neuromuscul Dis 2025 · Clinical Trial, Phase III, Multicenter Study
- Enzyme replacement therapy for late-onset Pompe disease.
Dalmia S, Sharma R, Ramaswami U, et al. · Cochrane Database Syst Rev 2023 · Systematic Review
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.